All In Biotech

Drug Trial Radar · NCT06599684

Study of INV-102 Ophthalmic Solution in Adults With Diabetic Macular Edema Associated With Non-proliferative Diabetic Retinopathy

Phase 2a Pilot, Open Label, Multicenter, Study of INV-102 Ophthalmic Solution in Subjects With Diabetic Macular Edema (DME) Associated With Non-proliferative Diabetic Retinopathy (NPDR)

Last checked: Nov 19, 2026Latest source record: Oct 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

19

Actual

Start

Sep 7, 2024

Primary completion

Sep 30, 2025

Study completion Sep 30, 2025

Sponsor

Lead sponsor
Invirsa, Inc.Industry
Sponsor type
Industry
Collaborators
Biomedical Advanced Research and Development Authority
First posted
Sep 19, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Phase 2 study to assess the efficacy of topically administered eyedrops of INV-102 during a 12-week dosing period in subjects with non-center involved DME (NCIDME) associated with NPDR \[Part 1\] and during an 8-week dosing period in subjects with center-involved DME (CIDME) associated with NPDR \[Part 2\].

Conditions

  • Non-center Involved Diabetic Macular Edema
  • Non-center Involved Diabetic Macular Edema Associated With Non-proliferative Diabetic Retinopathy
  • Diabetic Retinopathy
  • Center-involved Diabetic Macular Edema
  • Center-involved Diabetic Macular Edema Associated With Non-proliferative Diabetic Retinopathy

Interventions

  • INV-102Drug

    0.7% Ophthalmic Solution

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in the Early Treatment Diabetic Retinopathy (ETDRS) Diabetic Retinopathy Severity Scale (DRSS) scoreTime frame: Day 84 (Part 1) and Day 56 (Part 2)
  2. Change from baseline in central subfield thickness (Part 2 only)Time frame: Day 56

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • MedTrials, Inc.

    Dallas, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.